Evaluating higher doses of Ivermectin for COVID-19 treatment
Clinical Study Evaluating the Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment
This study is testing whether higher doses of Ivermectin can help people with COVID-19 feel better and recover faster.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Tanta) |
| Trial ID | NCT04351347 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the efficacy of administering larger doses of Ivermectin to patients diagnosed with COVID-19. The study is designed as an interventional trial, encompassing both Phase 2 and Phase 3 evaluations to assess the treatment's effectiveness and safety. Participants will receive Ivermectin, and their health outcomes will be monitored to determine any improvements in COVID-19 symptoms and recovery rates.
Who should consider this trial
Good fit: Ideal candidates for this study are patients who have been diagnosed with COVID-19.
Not a fit: Patients who have allergies or adverse reactions to Ivermectin will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients suffering from COVID-19.
How similar studies have performed: While some studies have explored the use of Ivermectin for COVID-19, the efficacy of higher doses remains a relatively novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with covid 19 Exclusion Criteria: * Allergy or side effects to treatment
Where this trial is running
Tanta
- Tanta University — Tanta, Egypt (Recruiting)
Study contacts
- Principal investigator: sherief Abd-Elsalam, Ass. Prof. — Tanta University - Faculty of Medicine
- Study coordinator: Sherief Abd-Elsalam, ass. prof.
- Email: sheriefabdelsalam@yahoo.com
- Phone: 00201147773440
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.